^
    Back
    Association details:
    Biomarker:MAPK1 R135K
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 1792: MAPK1 p.D321N mutation confers sensitive to erlotinib in head and neck squamous cell carcinoma (HNSCC)

    Published date:
    05/15/2020
    Excerpt:
    Subsequent laboratory investigation confirmed the ability of MAPK1 p.E322K to hyperactivate EGFR, thus causing erlotinib sensitivity in HNSCC models...Whereas MAPK1 p.R135K tumors only showed a trend for erlotinib sensitivity (P=0.0646), with reduction in membranous p-EGFR expression by erlotinib in the tumors. Thus, MAPK1 p.D321N mutation confers erlotinib-sensitivity in HNSCC system.
    DOI:
    10.1158/1538-7445.AM2020-1792
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Nature
    Title:

    Erlotinib sensitivity of MAPK1p.D321N mutation in head and neck squamous cell carcinoma

    Published date:
    04/20/2020
    Excerpt:
    ...we identified two MAPK1 mutations in recurrent HNSCC, MAPK1p.D321N, and p.R135K….Of note, among MAPK1p.R135K mutant xenografts, erlotinib treatment caused a trend for tumor size reduction (28.0% reduction vs. vehicle treatment; P = 0.0646; Fig. 2a)...
    DOI:
    10.1038/s41525-020-0124-5